|
Market Closed -
Nasdaq
23:00:00 28/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 10.62 USD | +3.51% |
|
+0.95% | +72.68% |
| 10-12 | ImmuCell Q3 Preliminary Sales Rise | MT |
| 10-12 | Immucell Corporation Reports Preliminary Unaudited Sales Results for the Third Quarter and Nine Months Ended September 30, 2026 | CI |
| Market Cap | 96.45M 86.54M 80.01M 72.46M 135M 9.19B 137M 957M 381M 4.81B 362M 354M 15.26B | P/E 2024 |
-19.5x | P/E 2025 | -51.3x |
|---|---|---|---|---|---|
| Enterprise Value | 106M 94.96M 87.79M 79.51M 149M 10.08B 150M 1.05B 418M 5.27B 397M 389M 16.75B | EV / Sales 2024 |
2.16x | EV / Sales 2025 | 2.35x |
| Free-Float |
67.73% | Yield 2024 * |
-
| Yield 2025 | - |
NasdaqUSD
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| ICCC | Delayed | |
CBOE
| ICCC | Real-time | |
Deutsche Boerse AG
| IUL | Delayed |
Last Transcript: ImmuCell Corporation
| 1 day | +3.51% | ||
| 1 week | +0.95% | ||
| Current month | +8.37% | ||
| 1 month | +7.49% | ||
| 3 months | -5.52% | ||
| 6 months | +27.19% | ||
| Current year | +72.68% |
| 1 week | 10.19 | 10.64 | |
| 1 month | 9.55 | 10.88 | |
| Current year | 5.75 | 12.1 | |
| 1 year | 4.52 | 12.1 | |
| 3 years | 3.34 | 12.1 | |
| 5 years | 3.34 | 12.1 | |
| 10 years | 0 | 13.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 01/11/2025 | |
Timothy Fiori
DFI | Director of Finance/CFO | 47 | 07/04/2025 |
| Comptroller/Controller/Auditor | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
David Tomsche
CHM | Chairman | 69 | 01/12/2013 |
Paul Wainman
BRD | Director/Board Member | 61 | 31/03/2014 |
Gloria Basse
BRD | Director/Board Member | 66 | 10/06/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 4/15/26 A | Free | Chairman | 11,933 | 0.1319% | ||
| 4/15/26 A | Free | Director | 17,899 | 0.1979% | ||
| 4/15/26 A | Free | Director | 11,933 | 0.1319% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +3.51% | +0.95% | +72.40% | +123.11% | 96.45M | ||
| +0.50% | +1.38% | +57.09% | +129.96% | 1,148B | ||
| +0.86% | +5.14% | +45.00% | +86.15% | 652B | ||
| -0.14% | +0.42% | +25.69% | +105.85% | 505B | ||
| +0.55% | +2.37% | +54.15% | +66.35% | 384B | ||
| -0.63% | -5.97% | +61.93% | +37.06% | 348B | ||
| +3.10% | +3.48% | +35.39% | +57.58% | 294B | ||
| +1.69% | +0.05% | +3.39% | +27.09% | 264B | ||
| +0.87% | +3.08% | +54.69% | +72.74% | 244B | ||
| +0.08% | +3.67% | +35.05% | +107.78% | 197B | ||
| Average | +2.13% | +1.34% | +44.48% | +81.37% | 403.73B | |
| Weighted average by Cap. | +2.30% | +1.50% | +45.03% | +89.28% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 26.49M 23.77M 21.98M 19.9M 37.18M 2.52B 37.63M 263M 105M 1.32B 99.42M 97.32M 4.19B | 27.64M 24.8M 22.93M 20.77M 38.8M 2.63B 39.27M 274M 109M 1.38B 104M 102M 4.37B |
| Net income | -2.16M -1.93M -1.79M -1.62M -3.03M -205M -3.06M -21.39M -8.52M -107M -8.09M -7.92M -341M | -1.04M -933K -863K -781K -1.46M -99.05M -1.48M -10.31M -4.11M -51.83M -3.9M -3.82M -165M |
| Net Debt | 11.34M 10.18M 9.41M 8.52M 15.92M 1.08B 16.11M 112M 44.8M 565M 42.56M 41.66M 1.79B | 9.39M 8.42M 7.79M 7.05M 13.18M 894M 13.34M 93.1M 37.08M 468M 35.23M 34.48M 1.49B |
Employees
73
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/10/26 | $10.62 | +3.51% | 924 |
| 27/10/26 | $10.26 | +0.20% | 4,167 |
| 26/10/26 | $10.24 | -0.10% | 2,557 |
| 23/10/26 | $10.25 | -1.82% | 11,335 |
| 22/10/26 | $10.44 | -0.76% | 5,772 |
- Stock Market
- Stocks
- ICCC Stock
Select your edition
All financial news and data tailored to specific country editions

















